Breast Cancer Prevention By A Soybean Protein.
Abstract
The goal of this project is to develop Bowman-Birk protease inhibitor (BBI), a soybean polypeptide,, as a chemopreventive agent for breast cancer. In order to achieve this goal, we proposed the fol owing two 5 specific aims in our original application: (1) using an in vitro mammary gland culture system to demonstrate the anti-transformation activity of both BBI and its palmitic acid conjugate (Pal-BBI , and (2) using a mouse model to demonstrate the advantages of Pal-BBI in oral delivery of BBI. During the first year, we have made important progress in both directions. First, we have established the cultured mammary gland system in our laboratory and have used this system to demonstrate the transformation induced by dimethylbenzA ANTHRACENE (DMBA). This transformation assay will allow us to further investigate ate the protective effect of BBI and Pal-BBI on the carcinogenesis of mammary lands. Secondly studies have been carried out on the comparison between the oral absorption of BBI and Pal- BBI. Preliminary results indicate that Pal-BBI, when used with a lipid formulation, can be absorbed via the gastrointestinal tract as an intact polypeptide. Further improvement on the oral delivery of Pal-BBI will be carried out during the second year of this project. In addition to the two specific aims, we have also developed an alternative method for the reparation of Pal-BBI by using partially reduced BBI to generate free sulfhydryl groups from cystinyl disulfide bonds for conjugation. Unlike the previous method that used chemically modified BBI as a starting material, this new method not only simplifies the preparation procedure, but also ensures a release of unmodified BBI from Pal-BBI in the target tissues.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1997
- Accession Number
- ADA332857
Entities
People
- Wei-chiang Shen
Organizations
- University of Southern California